Connective tissue disease associated with pulmonary arterial hypertension: Management of a patient with severe haemodynamic impairment

European Respiratory Review

Volumn 23, Issue 134, 2014, Pages 505-509

  Sitbon, Olivier ^a,b,c   Bertoletti, Laurent ^d,e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HÔPITAL NORD   (France)

^e University Jean Monnet of Saint Etienne EA3065   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; D DIMER; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTACYCLIN; RIBONUCLEOPROTEIN ANTIBODY; TADALAFIL; ANTIHYPERTENSIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTHRALGIA; CASE REPORT; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HEPATOMEGALY; HUMAN; LIVER PAIN; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; PATIENT CARE; PHYSICAL EXAMINATION; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SINUS TACHYCARDIA; THORAX PAIN; YOUNG ADULT; COMORBIDITY; CONNECTIVE TISSUE DISEASES; DISEASE MANAGEMENT; DRUG COMBINATION; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; COMORBIDITY; CONNECTIVE TISSUE DISEASES; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84914152589     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00009214     Document Type: Review

References (37)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697.
3. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
4. Gunnarsson R, Andreassen AK, Molberg Ø, et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 2013; 52: 1208-1213.
5. Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983; 68: 1182-1193.
6. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63: 92-107.
7. Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899-909.
8. Dorfmüller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
9. Okawa-Takatsuji M, Aotsuka S, Fujinami M, et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116: 174-180.
10. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue diseaseassociated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
11. Foïs E, Sitbon O. Systemic lupus erythmatosus-associated PAH: is targeting inflammation the key to success? Eur Respir Rev 2011; 20: 218-219.
12. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
13. Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich) 2014; 16: 122-126.
14. Ghofrani H-A, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 469-475.
15. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D60-D72
16. Watanabe R, Fujii H, Shirai T, et al. Successful use of intensive immunosuppressive therapy for treating simultaneously occurring cerebral lesions and pulmonary arterial hypertension in a patient with systemic lupus erythematosus. Intern Med 2014; 53: 627-631.
17. Prete M, Fatone MC, Vacca A, et al. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clin Exp Rheumatol 2014; 32: 267-274.
18. Okura Y, Takezaki S, Yamazaki Y, et al. Rapid progression to pulmonary arterial hypertension crisis associated with mixed connective tissue disease in an 11-year-old girl. Eur J Pediatr 2013; 172: 1263-1265.
19. Kato M, Kataoka H, Odani T, et al. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review. Lupus 2011; 20: 1047-1056.
20. Végh J, Soós G, Csipõ I, et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 2006; 26: 264-269.
21. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011; 75: 2668-2674.
22. Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
23. Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-287.
24. Schenk P, Petkov V, Madl C, et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001; 119: 296-300.
25. Vachiéry JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121: 1561-1565.
26. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003; 124: 1612-1615.
27. Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004; 126: 808-815.
28. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586-1589.
29. Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest 2006; 130: 1471-1480.
30. Johnson RF, Loyd JE, Mullican AL, et al. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007; 26: 363-369.
31. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007; 132: 757-763.
32. Safdar Z. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. Respir Med 2009; 103: 1688-1692.
33. Park K, Ostrow D, Levy RD, et al. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review. Can Respir J 2011; 18: 157-162.
34. de Jesus Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012; 110: 1546-1550.
35. Enderby CY, Soukup M, Al Omari M, et al. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series. J Clin Pharm Ther 2014; 39: 496-500.
36. Diaz-Guzman E, Heresi GA, Dweik RA, et al. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension. Respir Med 2008; 102: 681-689.
37. Minai OA, Parambil J, Dweik RA, et al. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Respir Med 2013; 107: 458-465.